STAT - Reporting from the frontiers of health and medicine

Special Report

Biotech

First Opinion

By Gary Marcus and Max A. Little

Health Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again
Biotech The country’s only diabetes-focused venture fund brings on a new partner
First Opinion Specialization improves return on capital in the life sciences
Pharmalot Biogen’s latest Alzheimer’s drug data may look good, but is it enough for FDA approval?
Heavyweights How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

The use of antibiotics in food-producing livestock continues to drop in most of Europe
Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations
Sanders, other lawmakers say FDA is not being transparent about Takeda’s recall of lifesaving drug

Special Report

Heavyweights

Health

Health

Health

By Brittany Flaherty

First Opinion

Biotech In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval
Special Report A livestock-poison-turned-drug might save her from endless cancer surgeries. But if she helps test it, could she afford to keep taking it?
In the Lab New CRISPR tool has the potential to correct almost all disease-causing DNA glitches, scientists report
Biotech Experts parse Biogen’s Alzheimer’s data: Does the treatment work, or is it a mirage?
First Opinion Advancing AI in health care: It’s all about trust